Jennison Associates
DYN icon

Jennison Associates’s Dyne Therapeutics DYN Stock Holding History

Jennison Associates’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,211,915
Closed -$28.6M – 589
2024
Q4 		$28.6M Sell
1,211,915
-135,037
-10% -$3.99M 0.02% 304
2024
Q3 		$48.4M Buy
1,346,952
+19,730
+1% +$785K 0.03% 234
2024
Q2 		$46.8M Buy
1,327,222
+119,671
+10% +$3.48M 0.03% 218
2024
Q1 		$34.3M Buy
1,207,551
+1,004,680
+495% +$22.7M 0.02% 277
2023
Q4 		$2.7M Buy
+202,871
New +$1.98M ﹤0.01% 444

Other funds holding DYN

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Jennison Associates's DYN Position: Q1 2025 in Review

Jennison Associates sold out of Dyne Therapeutics (DYN) in Q1 2025, closing a stake of 1,211,915 shares — an estimated $28.6M sold.

Jennison Associates first reported a position in DYN in Q4 2023 and held it in 5 quarters. The position peaked at $48.4M in Q3 2024. 205 funds tracked by Wall St. Rank hold DYN as of Q1 2025.

  • Jennison Associates reported no remaining Dyne Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Jennison Associates sold 1,211,915 Dyne Therapeutics shares in Q1 2025, an estimated $28.6M.
  • Jennison Associates first reported a position in Dyne Therapeutics in Q4 2023 and held it in 5 quarters.
  • Jennison Associates's Dyne Therapeutics position peaked at $48.4M in Q3 2024.
  • 205 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2025.

Based on Jennison Associates's 13F filing for Q1 2025, filed 5 May 2025.